Glenmark's molecule for pain therapy entering human trials

Glenmark Pharmaceuticals today said its novel chemical entity for potential treatment of chronic inflammatory

RELATED ARTICLES

disorders is entering human trials.

Glenmark has completed preclinical studies and Phase 1 enabling good laboratory practise for the molecule, GRC 27864, and has filed a Phase 1 application for first-in-human trial with the MHRA, UK, Glenmark Pharma said in a BSE filing.

The Phase 1 studies are to be initiated soon and are likely to get completed by January 2015, it added.

Glenmark Pharmaceuticals Ltd Chief Scientific Officer Michael Buschle said: "This is another first-in-class molecule and there is a significant unmet medical need. This announcement also reaffirms our position globally in the development of novel pain therapies."

Indicating potential and size of the market for the drug, the firm said: " 20% of the global adult population suffers from pain with 10% of newly diagnosed cases of chronic pain cases being added every year."

Following human trial, Glenmark will initiate a proof of concept study in patients with acute pain.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Healthy bottomlines are nothing if not backed by a happy work force

    Trust technology firms to devise solutions for every situation.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Tushar Gandhi

Bapu vs Netaji, a needless row

Once again, a rivalry from the past has been raked ...

Purnendu Ghosh

Eyes are our best social navigators

Eyes have a rich vocabulary. They can not only ...

Bubbles Sabharwal

The bitter cold heart of life

Life has a heart just as we do. Most times ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture